Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company has issued 140,321 new Ordinary Shares in settlement of an exercise of warrants. The exercise price of the warrants was 20 pence. The new Ordinary Shares represent 0.13% of the enlarged issued share capital.
Admission to trading on AIM of the 140,321 new Ordinary Shares, which rank parri passu with the existing Ordinary Shares, is expected on 28 September 2015. Following the allotment, the total issued share capital will increase to 108,486,537 Ordinary Shares with each share holding one voting right.
Enquiries
Motif Bio plc.
Graham Lumsden (Chief Executive Officer)
Robert Bertoldi (Chief Financial Officer)
www.motifbio.com
info@motifbio.com
MC Services AG (TRADE PR)
Raimund Gabriel
+49 (0) 89 210 2280
Shaun Brown
+44 (0) 207 148 5998
Zeus Capital Limited (NOMINATED ADVISER and BROKER)
+44 (0) 20 7533 7727
Phil Walker/ John Treacy
Dominic Wilson
Northland Capital Partners Limited (BROKER)
+44 (0) 20 7382 1100
Patrick Claridge/ David Hignell
John Howes/ Mark Treharne (Broking)
Plumtree Capital Limited (FINANCIAL ADVISOR)
+44 (0) 207 183 2493
Stephen Austin
Yellow Jersey PR Limited (FINANCIAL PR)
Dominic Barretto
Philip Ranger
Charles Goodwin
+44 (0) 7768 537 739
Help employers find you! Check out all the jobs and post your resume.
